ISSN 1007-9327 CN 14-1219/R
World J Gastroenterol 2010 August 28; 16(32): 4107-4111
CASE REPORT
Albert M Anderson, Marina B Mosunjac, Melody P Palmore, Melissa K Osborn, Andrew J Muir
Albert M Anderson, Marina B Mosunjac, Melody P Palmore, Melissa K Osborn, Emory University School of Medicine, Grady Health System Infectious Diseases Program, 341 Ponce de Leon Avenue, Atlanta, GA 30308, United States
Andrew J Muir, Duke University School of Medicine, DUMC 3913, Durham, North Carolina, CA 27710, United States
Author contributions: Anderson AM, Mosunjac MB, Palmore MP and Osborn MK performed the research; Mosunjac MB performed pathological analysis; Anderson AM and Muir AJ analyzed the research and wrote the paper.
Correspondence to: Albert M Anderson, MD, MHS, Emory University School of Medicine, Grady Health System Infectious Diseases Program, 341 Ponce de Leon Avenue, Atlanta, Georgia, GA 30308, United States.
aande2@emory.edu
Telephone: +1-404-6166864
Fax: +1-404-6169732
Received: April 1, 2010
Revised: May 31, 2010
Accepted: June 7, 2010
Published online: August 28, 2010
Abstract
Coinfection with hepatitis B virus (HBV) is not uncommon in human immunodeficiency virus (HIV)-infected individuals and patients with HIV-HBV coinfection are at high risk for progression of liver disease. Current guidelines regarding the treatment of HIV infection recommend that patients who are coinfected with HIV and HBV receive highly active antiretroviral therapy (HAART) with activity against hepatitis B. While HIV-HBV coinfected patients often experience liver enzyme elevations after starting antiretroviral therapy, acute liver failure (ALF) is rare and typically occurs with older antiretroviral agents with known potential for hepatotoxicity. We describe two cases of fatal ALF in the setting of HIV-HBV coinfection after initiation of HAART. These cases occurred despite treatment with antiretrovirals that have activity against HBV and highlight the challenges in distinguishing drug hepatotoxicity and HBV immune reconstitution inflammatory syndrome. HIV-HBV coinfected patients should be monitored closely when initiating HAART, even when treatment includes agents that have activity against HBV.
© 2010 Baishideng. All rights reserved.
Key words: Hepatitis B virus; Human immunodeficiency virus; Liver failure
Peer reviewers: Rosemary Joyce Burnett, MPH, Department of Epidemiology National School of Public Health, University of Limpopo, Medunsa Campus PO Box 173, MEDUNSA, Pretoria 0204, South Africa; Sang Hoon Ahn, MD, PhD, Associate Professor, Department of Internal Medicine, Institute of Gastroenterology and Hepatology, Yonsei University College of Medicine, Severance Hospital, 250 Seongsanno, Seoul, South Korea
Anderson AM, Mosunjac MB, Palmore MP, Osborn MK, Muir AJ. Development of fatal acute liver failure in HIV-HBV coinfected patients.
World J Gastroenterol 2010; 16(32): 4107-4111 Available from: URL:
http://www.wjgnet.com/1007-9327/full/v16/i32/4107.htm DOI:
http://dx.doi.org/10.3748/wjg.v16.i32.4107
INTRODUCTION
It is estimated that 10% of human immunodeficiency virus (HIV)-infected patients in the United States and Europe are chronically coinfected with hepatitis B virus (HBV)[1,2]. In other regions, rates of HBV coinfection in HIV-infected patients may be even higher[3]. HIV-HBV coinfected patients have higher rates of liver-related morbidity and mortality compared to patients infected with either virus alone[4,5]. Therefore, current guidelines suggest that HIV-infected patients with HBV infection should be treated with a highly active antiretroviral therapy (HAART) regimen that is also active against HBV[6]. However, HIV-HBV coinfected patients are particularly susceptible to certain complications of HAART. The vast majority of antiretroviral medications have been associated with some degree of hepatotoxicity and the presence of HBV infection is an independent risk factor for the development of clinically significant hepatotoxicity[7-9]. Additionally, coinfected patients are at risk for HBV immune reconstitution inflammatory syndrome (IRIS), which is characterized by a paradoxical hepatitis flare corresponding to an initial improvement in plasma HIV RNA level and CD4+ T-cell count on HAART[10]. Overall, liver enzyme elevations in HIV-HBV coinfected patients after starting HAART are not uncommon, but acute liver failure (ALF) is rare[11]. Reported cases have typically involved treatment with older thymidine analogue drugs such as stavudine and didanosine[12]. We describe two cases in which fatal ALF occurred in patients with HIV-HBV coinfection after beginning HAART regimens which did not include thymidine analogues but which did have activity against HBV.
CASE REPORT
Patient A
A 42-year-old African-American male with longstanding HIV/HBV coinfection was seen in clinic. He had been diagnosed with HIV infection over 10 years previously but had been on antiretrovirals for only short periods since diagnosis. As a result, his CD4+ T-cell count had reached a nadir of 5 cells/mL (1%) with a plasma HIV RNA level of 51 230 copies/mL. His plasma HBV DNA level was 147 million IU/mL. Both hepatitis B endogenous antigen (HBeAg) and anti-HBe antibody were negative. He was started on a new regimen of ritonavir-boosted atazanavir, lamivudine, and abacavir. At that time, his alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were both slightly elevated at 94 U/L (normal range 17-63 U/L) and 73 U/L (normal range 10-42 U/L), respectively, with a normal bilirubin level. The patient had never undergone a liver biopsy. Eight weeks after starting therapy, he returned to clinic with nausea, vomiting, and jaundice. The ALT level had increased to 1352 U/L and the AST was 1765 U/L. Total bilirubin was 14.1 mg/dL, direct bilirubin was 8.9 mg/dL, and prothrombin time was 18.9 s (INR 1.62). HIV RNA level had decreased to 100 copies/mL. He was admitted to the hospital for further workup. The patient did not drink alcohol and acetaminophen level was undetectable. Hepatitis C virus (HCV) RNA was undetectable, hepatitis D virus (HDV) antibody was negative, and hepatitis A virus (HAV) IgM was negative. HBV DNA had decreased to 4.42 million IU/mL. Anti-nuclear antibody screen was negative. All medications were held for 48 h. His ALT and AST levels decreased to 992 U/L and 1505 U/L. The appearance of the liver was normal on computed tomography of the abdomen with no suggestion of cirrhosis or portal hypertension. He was then discharged after starting a new regimen of ritonavir-boosted fosamprenavir, emtricitabine, and tenofovir. Ten days later he was re-admitted to the hospital with nausea, vomiting, and abdominal pain. ALT and AST levels had risen to 1214 U/L and 1992 U/L. Total bilirubin was 29.5 mg/dL, direct bilirubin was 18.3 mg/dL, and prothrombin time was 35.4 s (INR 3.19). HBV DNA level had decreased to 83 100 IU/mL. The ritonavir and fosamprenavir were discontinued and he was continued on emtricitabine/tenofovir. A liver biopsy showed marked septal fibrosis with nodule formation that was consistent with cirrhosis (Figure 1A and B). There was a severe mixed inflammatory infiltrate in portal and periportal areas containing lymphocytes, plasma cells and scant eosinophils (Figure 2A). The liver eosinophils were readily identified and no other special stains such as sirius red were used. Peripheral blood eosinophil count was within normal limits. Severe piecemeal necrosis was present diffusely around most of the portal tracts linking some of them together in so-called bridging necrosis (Figure 2B). After 10 d, his ALT and AST levels had come down to 405 U/L and 758 U/L, but total and direct bilirubin remained elevated at 28.8 mg/dL and 13.6 mg/dL. Due to concern for creating HIV resistance, he was switched from emtricitabine/tenofovir to adefovir. After 1 wk, he developed worsening renal failure and was switched from adefovir to emtricitabine and telbivudine. However, his condition continued to deteriorate. After 3 wk in the hospital, he became progressively encephalopathic, thrombocytopenic with a platelet count of 33 000/mL, and coagulopathic with prothrombin time of 37.7 s (INR 3.41). He developed hematemesis and became increasingly unresponsive with an ammonia level of 96 mmol/L (normal range 11-35 mmol/L). The patient was thought to be too unstable to undergo liver transplantation. After discussions with his family, he was placed on comfort care and died.
Patient B
A 46-year-old African-American male came to clinic with a new diagnosis of HIV infection. CD4+ T-cell count was 44 cells/mL (8%) with a plasma HIV RNA level of 9620 copies/mL. He was also diagnosed with hepatitis B infection with HBV DNA level > 500 million IU/mL. Duration of HBV infection was not known but HBV core IgM was negative. HCV antibody was negative, HBeAg was negative, anti-HBe antibody was positive, and HDV antibody was negative. ALT level was normal at 62 U/L and AST was slightly elevated at 53 U/L. He was started on a regimen of once daily ritonavir-boosted darunavir and tenofovir/emtricitabine. Five weeks after starting this regimen, he presented with nausea, vomiting, and jaundice. ALT was 1195 U/L and AST was 1396 U/L. Total bilirubin was 13.5 mg/dL, direct bilirubin was 7.7 mg/dL, and prothrombin time was 27.4 s (INR 2.42). HBV DNA level had decreased to 342 000 IU/mL. HIV RNA level was undetectable at < 50 copies/mL and CD4+ T-cell count was 52 cells/mL (10%). HAV IgM was negative and HCV antibody was negative on recheck. Both serum ethanol and acetaminophen levels were undetectable. The patient reported no sexual activity for over 1 year and he never used injectable drugs. Magnetic resonance imaging of the abdomen showed fibrotic changes throughout the liver and portal hypertension evidenced by splenomegaly, a recanalized umbilical vein and minimal perigastric and perisplenic varices. After all medications were held for 72 h, he was restarted on a regimen of ritonavir-boosted fosamprenavir and tenofovir/emtricitabine. Over the next week, his ALT and AST levels trended down to 803 U/L and 773 U/L and his platelets remained within normal limits. However, over that period of time his prothrombin time increased to 42.5 s (INR 3.88) and he became profoundly encephalopathic with an ammonia level of 137 mmol/L. The patient was thought to be too unstable for liver transplantation. After a total of 10 d in the hospital he developed cardiac arrest and died.
DISCUSSION
The development of elevated liver enzymes is not uncommon in HIV-HBV coinfected patients after starting HAART[13]. In the majority of cases, these elevations are mild and do not require modification of treatment[11]. The development of more severe hepatotoxicity (liver enzymes > 10 times the upper limit of normal) is not common and ALF is rare[9]. Among HIV-infected patients in general, those who develop ALF while on HAART have experienced very high rates of mortality[14]. Therefore, an HIV-HBV coinfected patient who develops ALF after starting HAART may be at particularly high risk for mortality, given the presence of underlying liver disease and potentially impaired reserve.
The most appropriate management of such patients is not completely clear, and the optimal management of HIV-HBV coinfected patients who develop liver enzymes > 10 times the upper limit of normal after starting HAART but who do not have evidence of decompensated liver disease may be even more difficult to delineate. One question is whether it is possible to determine if the hepatic injury is from drug toxicity or HBV IRIS and whether this changes management of the patient. Liver biopsy may be helpful in identifying an opportunistic infection, such as mycobacterial disease or cytomegalovirus, that may contribute to liver disease. Liver biopsy may also indicate the presence of cirrhosis. The latter was present in the case of patient A and would have also been found in the case of patient B given radiographic findings. In patient A, liver biopsy showed severe inflammation with lymphocytes, plasma cells, and scant eosinophils. Many cases of HAART-induced ALF in patients without HBV show only mild hepatic inflammatory cell infiltration on biopsy[15]. However, the presence of portal plasma-lymphocytic infiltrate is nonspecific and can be found in chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis and even some medication reactions[16]. The presence of eosinophils may be more specific for a drug reaction[17], though these were scant in this case. Overall, distinguishing between HBV IRIS and drug hepatotoxicity in such cases of ALF may not change management, particularly because it is not clear if anti-inflammatory medications such as corticosteroids are beneficial in HBV IRIS. Corticosteroids have been found to increase HBV replication[18] and this has led some to recommend against the use of corticosteroids in the setting of HBV IRIS[19].
The patients in our series met criteria for ALF according to the American Association for the Study of Liver Diseases guideline for liver failure[20]. In this guideline, it is recommended that “all non-essential medications” be discontinued in patients with ALF. Due to the fact that the majority of antiretrovirals, including protease inhibitors[8], have been associated with hepatotoxicity, it is advisable to hold HAART at least in the short term. However, HBV flares have been associated with the discontinuation of HAART regimens that contain anti-HBV activity[21]. This theoretically could contribute to ALF. At the same time, continuing single or dual therapy with anti-HBV agents such as lamivudine or tenofovir would create an environment in which HIV resistance might develop. This has led some to recommend stopping HAART and considering treatment of HBV with agents that do not have activity against HIV in cases of significant hepatitis flares on HAART in the setting of hepatitis B cirrhosis[22]. Adefovir is an option, but this drug has less potency against HBV than other agents[23]. Interferon a-based therapies might be considered, but are contraindicated in patients with decompensated cirrhosis. Entecavir was initially thought to have no significant anti-HIV activity, but has subsequently been shown to be associated with the development of HIV resistance mutations when used in the absence of other antiretrovirals[24]. One report suggests that telbivudine may also have activity against HIV[25]. Overall, we believe that the effort to help the patient survive an episode of ALF overrides the preservation of one particular antiretroviral class for future use and that at least one agent with anti-HBV activity should be given in such a scenario. In general, it appears that patients who develop liver failure on HAART, whether coinfected with HBV or not, have a very poor prognosis. These patients should be considered for liver transplantation evaluation, as emerging data show that HIV-HBV coinfected patients have excellent outcomes with liver transplantation[26].
It is prudent to closely monitor the clinical status and liver enzymes of HIV-HBV infected patients after initiation of HAART in order to identify cases of hepatotoxicity early on. Additionally, two new antiretroviral classes have been introduced in recent years. These include the integrase inhibitor class currently represented by raltegravir and the CCR5 antagonist class currently represented by maraviroc. Based on published reports to date, these new agents appear to have minimal hepatotoxicity[27]. While they have only been available since 2007 and toxicities have yet to be fully described, these agents hold promise for HIV-infected patients with chronic liver diseases such as HBV. Perhaps most importantly, efforts should be made to prevent the acquisition of chronic HBV infection, and the HBV vaccine is recommended for all patients with HIV infection[28].
REFERENCES
1 Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.
AIDS 2005; 19: 593-601
2 Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS).
Lancet 2002; 360: 1921-1926
3 Rouet F, Chaix ML, Inwoley A, Anaky MF, Fassinou P, Kpozehouen A, Rouzioux C, Blanche S, Msellati P. Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
Clin Infect Dis 2008; 46: 361-366
4 Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.
Hepatology 1999; 29: 1306-1310
5 Puoti M, Airoldi M, Bruno R, Zanini B, Spinetti A, Pezzoli C, Patroni A, Castelli F, Sacchi P, Filice G, Carosi G. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects.
AIDS Rev 2002; 4: 27-35
6 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents.
Bethesda: Department of Health and Human Services. December 1, 2009
7 Cooper CL. HIV antiretroviral medications and hepatotoxicity.
Curr Opin HIV AIDS 2007; 2: 466-473
8 Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors.
Semin Liver Dis 2003; 23: 183-194
9 Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
J Infect Dis 2002; 186: 23-31
10 Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.
Medicine (Baltimore) 2002; 81: 213-227
11 den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
AIDS 2000; 14: 2895-2902
12 Vogel M, Rockstroh JK. Hepatotoxicity and liver disease in the context of HIV therapy.
Curr Opin HIV AIDS 2007; 2: 306-313
13 Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Am J Med Sci 2007; 334: 334-341
14 Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F, Carosi G. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome.
J Acquir Immune Defic Syndr 2003; 32: 259-267
15 Clark SJ, Creighton S, Portmann B, Taylor C, Wendon JA, Cramp ME. Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases.
J Hepatol 2002; 36: 295-301
16 Watanabe S, Deguchi A, Uchida N, Kurokohchi K, Arima K, Nishioka M, Hasui H. Histopathologic comparison of anti-mitochondrial antibody-positive primary biliary cirrhosis and autoimmune cholangiopathy.
Hepatol Res 2001; 19: 41-51
17 Kleiner DE. The pathology of drug-induced liver injury.
Semin Liver Dis 2009; 29: 364-372
18 Sagnelli E, Manzillo G, Maio G, Pasquale G, Felaco FM, Filippini P, Izzo CM, Piccinino F. Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis.
Lancet 1980; 2: 395-397
19 Lesho E. Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome.
Expert Rev Anti Infect Ther 2006; 4: 469-478
20 Polson J, Lee WM. AASLD position paper: the management of acute liver failure.
Hepatology 2005; 41: 1179-1197
21 Nüesch R, Ananworanich J, Srasuebkul P, Chetchotisakd P, Prasithsirikul W, Klinbuayam W, Mahanontharit A, Jupimai T, Ruxrungtham K, Hirschel B. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection.
AIDS 2008; 22: 152-154
22 Crane M, Matthews G, Lewin SR. Hepatitis virus immune restoration disease of the liver. Curr Opin HIV
AIDS 2008; 3: 446-452
23 Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
N Engl J Med 2008; 359: 2442-2455
24 Sasadeusz J, Audsley J, Mijch A, Baden R, Caro J, Hunter H, Matthews G, McMahon MA, Olender SA, Siliciano RF, Lewin SR, Thio CL. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
AIDS 2008; 22: 947-955
25 Low E, Cox A, Atkins M, Nelson M. Telbivudine has activity against HIV.
16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal, Canada
26 Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity.
AIDS 2009; 23: 1069-1076
27 Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
J Antimicrob Chemother 2010; 65: 543-547
28 Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.
Clin Infect Dis 2009; 49: 651-681
S- Editor Wang JL L- Editor Logan S E- Editor Zheng XM
Source
